- Home
- VANI vs IKNA Comparison
VANI vs IKNA Comparison
Compare VANI & IKNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VANI
- IKNA
- Stock Information
- Founded
- VANI 1998
- IKNA 2016
- Country
- VANI United States
- IKNA United States
- Employees
- VANI N/A
- IKNA N/A
- Industry
- VANI Biotechnology: Electromedical & Electrotherapeutic Apparatus
- IKNA Biotechnology: Pharmaceutical Preparations
- Sector
- VANI Health Care
- IKNA Health Care
- Exchange
- VANI Nasdaq
- IKNA Nasdaq
- Market Cap
- VANI 68.1M
- IKNA 61.8M
- IPO Year
- VANI 2014
- IKNA 2021
- Fundamental
- Price
- VANI $1.15
- IKNA $1.36
- Analyst Decision
- VANI Strong Buy
- IKNA Strong Buy
- Analyst Count
- VANI 1
- IKNA 1
- Target Price
- VANI $4.00
- IKNA $4.00
- AVG Volume (30 Days)
- VANI 136.2K
- IKNA 95.6K
- Earning Date
- VANI 08-12-2025
- IKNA 08-07-2025
- Dividend Yield
- VANI N/A
- IKNA N/A
- EPS Growth
- VANI N/A
- IKNA N/A
- EPS
- VANI N/A
- IKNA N/A
- Revenue
- VANI N/A
- IKNA N/A
- Revenue This Year
- VANI N/A
- IKNA N/A
- Revenue Next Year
- VANI N/A
- IKNA N/A
- P/E Ratio
- VANI N/A
- IKNA N/A
- Revenue Growth
- VANI N/A
- IKNA N/A
- 52 Week Low
- VANI $0.91
- IKNA $0.97
- 52 Week High
- VANI $1.50
- IKNA $1.94
- Technical
- Relative Strength Index (RSI)
- VANI 54.56
- IKNA 56.43
- Support Level
- VANI $1.13
- IKNA $1.10
- Resistance Level
- VANI $1.25
- IKNA $1.46
- Average True Range (ATR)
- VANI 0.05
- IKNA 0.07
- MACD
- VANI -0.01
- IKNA -0.00
- Stochastic Oscillator
- VANI 29.05
- IKNA 57.58
About VANI Vivani Medical Inc. (DE)
Vivani Medical Inc is a preclinical-stage biopharmaceutical company. The company develops miniaturized, subdermal implants utilizing its proprietary NanoPortal technology to enable long-term, near-constant-rate delivery of a broad range of medicines to treat chronic diseases. It has two reporting segments, the Biopharm Division and the Neuromodulation Division. The Biopharm Division includes activities from NPM and Vivani Medical Australia Pty Ltd, and the Neurostimulation Division includes activities from Cortigent and its subsidiary in Switzerland.
About IKNA Ikena Oncology Inc.
Ikena Oncology Inc is a targeted oncology company developing precision therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the Hippo and RAS onco-signaling network. Its targeted oncology product candidate, IK-930, is an oral small-molecule inhibitor of the transcriptional enhanced associate domain, or TEAD, a transcription factor in the Hippo signaling pathway, a known oncogenic pathway that also drives resistance to multiple targeted and chemotherapies. Its other product candidates are IK-175 and IK-595.